TERADATA CORP /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TERADATA CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $626.00M | Feb 23, 2018 |
| FY2017 | Sep 30, 2017 | $526.00M | Feb 23, 2018 |
| FY2017 | Jun 30, 2017 | $513.00M | Feb 23, 2018 |
| FY2017 | Mar 31, 2017 | $491.00M | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | $626.00M | Feb 23, 2018 |
| FY2017 | Sep 30, 2016 | $552.00M | Feb 23, 2018 |
| FY2017 | Jun 30, 2016 | $599.00M | Feb 23, 2018 |
| FY2017 | Mar 31, 2016 | $545.00M | Feb 23, 2018 |
| FY2016 | Dec 31, 2015 | $719.00M | Feb 27, 2017 |
| FY2016 | Sep 30, 2015 | $606.00M | Feb 27, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.66B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.75B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.83B | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $1.80B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $1.92B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $1.84B | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $494.00M | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $459.00M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $478.00M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | $468.00M | Feb 28, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $987.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.06B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.12B | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $1.08B | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $1.19B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $1.02B | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $248.00M | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $247.00M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $236.00M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | $224.00M | Feb 28, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $114.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $62.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $33.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $147.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $129.00M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | ($19.00M) | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $10.00M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | ($1.00M) | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | ($10.00M) | Feb 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $205.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $209.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $186.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $118.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $231.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $16.00M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | ($5.00M) | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $10.00M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $10.00M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | ($5.00M) | Feb 28, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $280.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $284.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $294.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $313.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $309.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $334.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $327.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $317.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $305.00M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $212.00M | Mar 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $502.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $565.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $635.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $650.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $646.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $669.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $618.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $666.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $651.00M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $662.00M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $305.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $303.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $375.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $419.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $463.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $267.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $148.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $364.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $324.00M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $446.00M | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $24.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $19.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $14.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $28.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $44.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $54.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $153.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $78.00M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $53.00M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.78B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.70B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.87B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $2.02B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $2.17B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $2.19B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.06B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.36B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $2.56B | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.41B | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.55B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.57B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.74B | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $1.76B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.71B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.79B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.80B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.87B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $1.89B | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.44B | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $230.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $133.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $135.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $258.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $460.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2020 | $400.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2019 | $262.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $495.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $668.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $971.00M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $399.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $394.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $398.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $390.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $396.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $401.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $396.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $395.00M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $399.00M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $390.00M | Feb 23, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.92B) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($1.91B) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($1.81B) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($1.57B) | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | ($1.21B) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($1.11B) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($1.14B) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($823.00M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($579.00M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($161.00M) | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $493.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $420.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $486.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $569.00M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $592.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $529.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $494.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $715.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.09B | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $974.00M | Mar 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 28, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 28, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 92.50M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 95.10M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 97.90M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 101.10M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 107.20M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 108.80M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 110.90M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 116.80M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 121.90M | Mar 1, 2019 |